3 Healthy Stocks With Recent Upgrades

The markets have been hitting fresh highs.

It has some investors wondering — will it keep going like this? Or is a correction just around the corner?

If you're caught in that loop, don't despair. Instead, look for solid stocks that could benefit either way.

 We found three for you below. 

How did we find them? With Zen Ratings. To find the below picks, we focused stocks with recent Zen Rating upgrades to A (Strong Buy) or B (Buy), narrowing down the choices to a select class of stocks with higher-than-average potential to beat the market. 

A note from our sponsors...

1. Kroger Co (NYSE: KR)

Grocery stores as a whole often do fine regardless of the economic environment, and KR is no exception. Top-rated analysts forecast 25% or more upside for KR, dividends are up, and the grocery store industry as a whole is one of our top-ranked industries.

Plus, KR could be a great value right now.

The stock is down over the 3 months. However, our Zen Ratings system paints an optimistic picture — KR was recently upgraded to a B (Buy) rating. The fact that it also has B (above average) Component Grades for Value, Growth, Safety, and from our proprietary AI factor, suggest KR could be an excellent buy the dip opportunity.

2. Nutex Health Inc (NASDAQ: NUTX)

An operator of small and specialty hospitals, among other technology-related ventures, NUTX has had a fantastic run since late March in terms of its share price, and remains a potentially excellent value choice for investors.

That being said, unlike many stocks that focus on health, nutrition, and the like, NUTX is not necessarily the safest choice. It’s currently dealing with legal troubles concerning investor lawsuits, and While it makes up for matters in other areas, it has a very poor component grade for safety (see below). The risk-averse will be better served elsewhere. However, for those willing to take the relative risk, the value proposition is a serious one.

3. Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)

On the biotech and pharmaceutical side of things, there’s MIRM, which focuses primarily on rare diseases, with a few leading product candidates for intrahepatic cholestasis. While one can never be certain about such specialized companies, with future revenue concerns often looming, MIRM looks to be a current leader among stocks of its type.

Mirum as a potential investment (with its Component Grades in mind) is also looking a lot like NUTX in that its a relatively risky consideration with a lot of potential behind it. Analysts we follow also all consider it a strong buy. While you may or may not want it in your portfolio now, it is absolutely worth following further.

Are you looking for additional information about the stocks above, want to keep an eye on them, and more? Then WallStreetZen Premium is for you. With it, you’ll get an unlimited watchlist, all of the fundamental information you need, and greater ability to make investment decisions with peace of mind.

Want a more guided approach? Then you’ll want to look into Zen Investor. With it, you’ll receive regular updates from our own Steve Reitmeister, portfolio recommendations, members-only webinars, and more. It’s the perfect option for those who don’t want to worry about every little news item that comes along.

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.